Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234

Journal of Clinical Oncology

Volumn 32, Issue 23, 2014, Pages 2486-2495

  Harari, Paul M ^a   Harris, Jonathan ^b   Kies, Merrill S ^c   Myers, Jeffrey N ^c   Jordan, Richard C ^d   Gillison, Maura L ^f   Foote, Robert L ^h   Machtay, Mitchell ^g   Rotman, Marvin ⁱ   Khuntia, Deepak ^e   Straube, William ^j   Zhang, Qiang ^b   Ang, Kian ^c  

^a University of Wisconsin Health   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VARIAN MEDICAL SYSTEMS   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; HEMOGLOBIN; PROTEIN P16; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONNECTIVE TISSUE DISEASE; DEHYDRATION; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FIBROSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY; HYPOPHARYNX CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; LARYNX SQUAMOUS CELL CARCINOMA; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPHIL COUNT; ORAL MUCOSITIS; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN FIBROSIS; STOMATITIS; THROMBOCYTE COUNT; VERY ELDERLY; WEIGHT REDUCTION; XEROSTOMIA; ADJUVANT CHEMORADIOTHERAPY; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; CONTROLLED STUDY; HEAD AND NECK NEOPLASMS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE CARE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84905817727     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.9163     Document Type: Article

References (25)

1. Tupchong L, Scott CB, Blitzer PH, et al: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 20:21-28, 1991
2. Peters LJ, Goepfert H, Ang KK, et al: Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 26:3-11, 1993 (Pubitemid 23137882)
3. Bernier J, Domenge C, Ozsahin M, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952, 2004 (Pubitemid 38580197)
4. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944, 2004
5. Pignon JP, le Maître A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
6. Bernier J, Cooper JS, Pajak TF, et al: Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27:843-850, 2005 (Pubitemid 41395696)
7. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
8. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006 (Pubitemid 43209104)
9. Curran D, Giralt J, Harari PM, et al: Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25: 2191-2197, 2007 (Pubitemid 46954642)
10. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
11. Glisson BS: The role of docetaxel in the management of squamous cell cancer of the head and neck. Oncology (Williston Park) 16:83-87, 2002
12. Nakata E, Hunter N, Mason K, et al: C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys 59:1163-1173, 2004 (Pubitemid 38834311)
13. Rosenthal DI, Harris J, Forastiere AA, et al: Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: Report of the phase II trial RTOG 0024. J Clin Oncol 27:4727-4732, 2009
14. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
15. Dixon DO, Simon R: Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 41:1209-1213, 1988 (Pubitemid 19036523)
16. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Kalbfleisch J, Prentice R: The Statistical Analysis of Failure Data. New York, NY, John Wiley and Sons, 1980
18. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
19. Cox D: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
20. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
21. Ang KK, Trotti A, Brown BW, et al: Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 51:571-578, 2001
22. Ang KK, Zhang Q, Rosenthal DI, et al: Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck carcinoma: RTOG 0522. J Clin Oncol doi:10.1200/JCO.2013.53.5633
23. Wang M, Morsbach F, Sander D, et al: EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 71:6261-6269, 2011
24. Zhang F, Zhang T, Qu Y, et al: Replication-dependent -H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep 24:1297-1305, 2010
25. Peters LJ, O'Sullivan B, Giralt J, et al: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J Clin Oncol 28:2996-3001, 2010